These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 37101094)

  • 1. Myasthenia gravis, respiratory function, and respiratory tract disease.
    Gilhus NE
    J Neurol; 2023 Jul; 270(7):3329-3340. PubMed ID: 37101094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
    Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
    Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myasthenic Crisis as the First Presentation of Myasthenia Gravis: A Case Report.
    Payus AO; Leow Wen Hsiang J; Leong JQ; Ibrahim A; Raymond AA
    Am J Case Rep; 2021 Jan; 22():e928419. PubMed ID: 33468985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed Diagnosis of Atypical Presentation of Myasthenia Gravis.
    Mustafa MS; Marshal M; Ahern E; Crowley P
    Eur J Case Rep Intern Med; 2018; 5(2):000785. PubMed ID: 30756011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment considerations in myasthenia gravis for the pregnant patient.
    Gilhus NE
    Expert Rev Neurother; 2023 Feb; 23(2):169-177. PubMed ID: 36786092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence.
    Gilhus NE; Hong Y
    Eur J Neurol; 2018 Dec; 25(12):1402-1409. PubMed ID: 30133097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myasthenia gravis: management of myasthenic crisis and perioperative care.
    Juel VC
    Semin Neurol; 2004 Mar; 24(1):75-81. PubMed ID: 15229794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Starting eculizumab as rescue therapy in refractory myasthenic crisis.
    Vinciguerra C; Bevilacqua L; Toriello A; Iovino A; Piscosquito G; Calicchio G; Barone P
    Neurol Sci; 2023 Oct; 44(10):3707-3709. PubMed ID: 37306795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis.
    de Meel RHP; Tannemaat MR; Verschuuren JJGM
    Neuromuscul Disord; 2019 Sep; 29(9):664-670. PubMed ID: 31488385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia Gravis and Crisis: Evaluation and Management in the Emergency Department.
    Roper J; Fleming ME; Long B; Koyfman A
    J Emerg Med; 2017 Dec; 53(6):843-853. PubMed ID: 28916122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel case of inclusion body myositis and myasthenia gravis.
    Lambrianides S; Kinnis E; Cleanthous M; Papacharalambous R; Panayiotou E; Zamba-Papanicolaou E; Kyriakides T
    Neuromuscul Disord; 2019 Oct; 29(10):771-775. PubMed ID: 31604651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myasthenia gravis].
    Schodrowski J; Seipelt M; Adibi-Sedeh I; Eienbröker C; Tackenberg B
    Internist (Berl); 2016 Apr; 57(4):349-61. PubMed ID: 27000188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPAP therapy reverses weakness of myasthenia gravis: role of obstructive sleep apnea in paradoxical weakness of myasthenia gravis.
    Ji KH; Bae JS
    J Clin Sleep Med; 2014 Apr; 10(4):441-2. PubMed ID: 24733991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis and risks for comorbidity.
    Gilhus NE; Nacu A; Andersen JB; Owe JF
    Eur J Neurol; 2015 Jan; 22(1):17-23. PubMed ID: 25354676
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.